Clinical trial
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide…
NCT00478777 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00478777 |
|---|---|
| Title | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma |
| Official title | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsed or Refractory Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Lenalidomide, dexamethasone |
| Enrollment | 150 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Aug 1, 2009 |
| First posted | May 25, 2007 |
| Last update posted | Nov 3, 2011 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: